Comments
Zydus Lifesciences Ltd has received final approvals from the United States Food and Drug Administration (USFDA) to manufacture and market Pimavanserin Capsules, 34 mg and Pimavanserin Tablets, 10 mg.
The capsules will be manufactured at the group’s formulation manufacturing facility at Ahmedabad SEZ, India.
The stock inched up by 0.37 per cent on the NSE, traded at ₹712.35 as of 9:20 am.
Comments
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.